News Releases

March 6, 2019
Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2019-- Synlogic, Inc ., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the advancement of Synthetic Biotic medicines to the lead optimization stage in its...
March 5, 2019
Synlogic Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2018 financial results before the...
February 28, 2019
Synlogic to Present at Investor Conferences in March
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will present at the following upcoming investor conferences: Chardan’s 1 st Annual Microbiome Medicines Summit at 2:05pm ET...
February 20, 2019
Synlogic to Webcast Presentation at the SVB Leerink 8th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 20, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the SVB Leerink 8th Annual Global Healthcare Conference at 1:30 pm ET on Thursday,...
February 12, 2019
Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2019-- Synlogic, Inc. , (Nasdaq:SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Patricia N. Hurter , Ph.D., Senior Vice President of Pharmaceutical...
January 16, 2019
Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for Hyperammonemia
–Phase 1 clinical trial to evaluate safety and tolerability of SYNB1020 in healthy volunteers demonstrated safety, clearance and proof of mechanism– – Data from ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia expected mid-2019 – CAMBRIDGE, Mass....
January 3, 2019
Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 Catalysts
– Presentation of topline clinical data from studies of Synthetic Biotic™ medicines, SYNB1020 and SYNB1618, in patients expected mid-2019 – – Investigational New Drug (IND) application for SYNB1891, Synlogic’s first immuno-oncology program, expected in 2H2019 – CAMBRIDGE, Mass....
December 12, 2018
Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM Medicines
– Good Manufacturing Process (GMP) infrastructure enables advancement of clinical programs through early and mid-phase studies – – Capabilities support production of both liquid and solid oral formulations – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 12, 2018-- Synlogic, Inc....
November 20, 2018
Synlogic to Webcast Presentation at the 30th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 30th Annual Piper Jaffray Healthcare Conference at 8:30 am ET on Wednesday, November...
November 13, 2018
Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates
– Advancement of SYNB1891, the first Synthetic Biotic™ immuno-oncology candidate to enable Investigational New Drug Application (IND) filing in 2H 2019 – – Ongoing clinical trials of SYNB1020 and SYNB1618 in patients with data expected in 2019 – – Management to host conference call and webcast at...
November 12, 2018
Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
- Data support ongoing evaluation of Synthetic Biotic TM SYNB1020 for the potential treatment of hyperammonemia - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 12, 2018-- Synlogic, Inc.  (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial...
November 7, 2018
Synlogic Announces Third Quarter 2018 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), announced today that the Company will release its third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018 . The press release will be followed by a conference call at 5:00 p.m....
Displaying 73 - 84 of 146